메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards

Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, today announced it has been named the winner of the "Best ADC Preclinical Publication 2024" at the 12th Annual World ADC Awards, recognizing the company's innovative research publication on the AJICAP® linker technology. The honored
- 김갑성 기자
- 2025-11-17 22:26
Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs

BOSTON, Nov. 17, 2025 -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its oversubscribed Series A-2 financing, closed at a substantial valuation step-up over the prior round. This Series A-2 financing reflects strong participation from Bambusa's existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners L.P., Salvia GmbH, Janus Henderson Investors, Inv
- 김갑성 기자
- 2025-11-17 22:15
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.[1] POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic thera
- 김갑성 기자
- 2025-11-17 22:06
Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

DURHAM, N.C. and SEOUL, South Korea, Nov. 17, 2025 -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care. The collaboration aims to leverage Labcorp's extensive clinical and pathology expertise alongside Lunit's cutting-edge AI algorithms to transform how tumor microenvironments are analyzed and in
- 김갑성 기자
- 2025-11-17 22:00
WALOVI International Cans Make Malaysian Debut, Shining at Fortune Innovation Forum

GUANGZHOU, China, Nov. 17, 2025 -- On November 17, 2025, at the Fortune Innovation Forum held in Kuala Lumpur, Guangzhou Wang Lao Ji Great Health Industry Co., Ltd., under Guangzhou Pharmaceutical Holdings Limited, grandly launched its WALOVI international cans in the Malaysian market. Following its successful launch in Singapore on November 7, this move represents another crucial strategic deployment for Wanglaoji within the ASEAN market, marking a new phase of deepened global expansion. At the launch ceremony, Tang Heping, Chief Accountant of Guangzhou Pharmaceutical Holdings
- 김갑성 기자
- 2025-11-17 19:40
Krinwave Expands Boundaries of Medical Imaging Using NVIDIA Jetson Thor

SHENZHEN, China, Nov. 17, 2025 -- Krinwave Technology, an innovator in medical imaging, announced plans to release one of the first ultrasound device powered by NVIDIA Jetson Thor. The device fully leverages Jetson Thor's powerful computing performance to support the high-performance requirements of Krinwave's proprietary kOS ultrasound system. This demonstrates an early application of Jetson Thor in ultrasound imaging, further extending its presence in medical imaging and unlocking the potential of advanced computing in diagnostic innovation. Krinwave's proprietary kOS system,
- 김갑성 기자
- 2025-11-17 18:11
AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment

HONG KONG, Nov. 17, 2025 -- The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in Cancer Management, convened in Hong Kong on November 1, marking Lung Cancer Awareness Month with a clear message: AI and multi-omics are no longer theoretical - they are driving real-world advancements in cancer care across the Asia-Pacific (APAC) region. Co-organized by the Hong Kong Precision Oncology Society, The Hong Kong Polytechnic University, the Hong Kong Integrated Oncology Centre, the Artificial Intelligence Association of Hong Kong, and supported
- 김갑성 기자
- 2025-11-17 13:45
Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China

HONG KONG, Nov. 17, 2025 -- Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expressed receptor, has been granted approval by the National Medical Products Administration (NMPA) to initiate clinical trials for Alzheimer's Disease. AK152 is the first bispecific antibody developed in China for disease-modifying therapy in Alzheimer's Disease, marking a significant breakthrough in the field. Furthermore, it is Akeso's first innovative therapeutic candidate designed to target the central nervous
- 김갑성 기자
- 2025-11-17 10:29
WellsCare Partners with SolnanoMed to Launch IASO and IASO Ultra in Thailand

[ 메디채널 김갑성 기자 ] Partnership to Bring Innovative Wearable Cold-Laser Therapy to One of Southeast Asia's Fastest-Growing Healthcare Markets SEOUL, South Korea, Nov. 17, 2025 -- WellsCare Inc., a leading South Korean med-tech innovator in wearable cold-laser therapy, today announced that it has signed a supply agreement with SolnanoMed Co., Ltd., one of Thailand's most respected medical device distributors. The agreement follows WellsCare's recent FDA Thai approval for its flagship product, IASO Coldlaser — advanced photobiomodulation (PBM) therapy device designed for effective, drug-fr
- 김갑성 기자
- 2025-11-17 10:00
Fotona Appoints Aimee Desrosiers as Global Chief Marketing Officer

DALLAS, Nov. 16, 2025 -- Fotona, a global leader in high-performing laser systems and energy-based devices for aesthetic, dental and gynecological applications, today announces the appointment of Aimee Desrosiers as Global Chief Marketing Officer. In this role, Desrosiers will lead Fotona's global marketing organization, guiding brand strategy, digital transformation, and market expansion efforts across more than 70 countries worldwide. Desrosiers is a seasoned leader and marketer with experience partnering with high-growth organizations to accelerate brand and commerci
- 김갑성 기자
- 2025-11-16 18:12

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분